Skip to content

Dietary Interventions for Irritable Bowel Syndrome

The Effects of a Low-FODMAP Diet and Gluten-Free and Lactose-Free Dietary Interventions on Symptoms in Patients Diagnosed With Irritable Bowel Syndrome

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07774923
Acronym
IBS-DIET
Enrollment
60
Registered
2026-08-19
Start date
2025-02-25
Completion date
2025-07-18
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Keywords

Low-FODMAP Diet, Gluten-Free Diet, Lactose-Free Diet, Dietary Intervention, Gastrointestinal Symptoms, IBS Symptom Severity Score

Brief summary

Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by recurrent abdominal pain and altered bowel habits. Dietary factors may trigger or worsen symptoms such as abdominal pain, bloating, gas, diarrhea, and constipation. This study evaluated and compared the effects of a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low-FODMAP) diet and a combined gluten-free and lactose-free diet on symptom severity in adults diagnosed with IBS. Adults aged 19-64 years with IBS followed one of the two dietary interventions for six weeks. IBS symptom severity was assessed at baseline and at the end of week 6 using the Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS). Dietary adherence was monitored by telephone during the intervention.

Detailed description

This interventional, parallel-group study was conducted at the Gastroenterology Outpatient Clinic of Mersin University Hospital between February 25 and July 18, 2025. The study included adults aged 19-64 years who had been diagnosed with irritable bowel syndrome, met the eligibility criteria, provided written informed consent, and agreed to follow the assigned dietary intervention. Participants followed either a low-FODMAP diet or a combined gluten-free and lactose-free diet for six weeks. The low-FODMAP intervention restricted foods high in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. The combined gluten-free and lactose-free intervention excluded foods containing gluten and lactose. Participants received detailed dietary instructions during the initial face-to-face visit. At baseline, a researcher administered a data collection form covering sociodemographic characteristics, health information, dietary habits, and food preparation and cooking practices. Gastrointestinal symptom severity was measured using the Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS). The IBS-SSS produces a total score ranging from 0 to 500, with higher scores indicating greater symptom severity. It assesses abdominal pain severity, frequency of abdominal pain, abdominal bloating, satisfaction with bowel habits, and the interference of bowel symptoms with daily life. Participants were contacted by telephone one week after starting the diet and subsequently at two-week intervals to monitor adherence. At the end of the six-week intervention, the IBS-SSS was administered again during a face-to-face visit. The primary analysis evaluated the change in IBS-SSS total score from baseline to week 6 and compared symptom changes between the two dietary intervention groups.

Interventions

BEHAVIORALLow-FODMAP Diet

Participants followed a low-FODMAP diet for six weeks. Foods high in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols were restricted. Participants received detailed dietary instructions during the initial face-to-face visit. Dietary adherence was monitored by telephone one week after starting the intervention and subsequently at two-week intervals.

BEHAVIORALGluten-Free and Lactose-Free Diet

Participants followed a combined gluten-free and lactose-free diet for six weeks. Foods containing gluten and lactose were excluded. Participants received detailed dietary instructions during the initial face-to-face visit. Dietary adherence was monitored by telephone one week after starting the intervention and subsequently at two-week intervals.

Sponsors

Istanbul Gelisim University
Lead SponsorOTHER
Bahçeşehir University
CollaboratorOTHER
Mersin University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

No masking was applied because participants and researchers were aware of the assigned dietary intervention.

Intervention model description

Participants followed one of two dietary interventions for six weeks: a low-FODMAP diet or a combined gluten-free and lactose-free diet. Each participant remained in the same intervention arm throughout the study, with no crossover between arms.

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Adults aged 19-64 years * Diagnosed with irritable bowel syndrome * Male or female * Provided written informed consent to participate in the study

Exclusion criteria

* Pregnancy or lactation * Diagnosis of cancer * Presence of a gastrointestinal disease other than irritable bowel syndrome * Diagnosis of diabetes mellitus * Diagnosis of a psychiatric disorder

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Irritable Bowel Syndrome Symptom Severity Score at Week 6Baseline and Week 6The Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS) was used to assess overall IBS symptom severity. The instrument includes five domains: abdominal pain severity, frequency of abdominal pain, abdominal bloating severity, satisfaction with bowel habits, and interference of bowel symptoms with daily life. The total score ranges from 0 to 500, with higher scores indicating greater symptom severity. Change was calculated as the week 6 score minus the baseline score; a negative change indicates improvement.

Secondary

MeasureTime frameDescription
Change From Baseline in Abdominal Pain Severity at Week 6Baseline and Week 6Abdominal pain severity was assessed using the corresponding IBS-SSS domain, scored from 0 to 100. Higher scores indicate greater abdominal pain severity. Change was calculated as the week 6 score minus the baseline score; a negative change indicates improvement.
Change From Baseline in Abdominal Pain Frequency at Week 6Baseline and Week 6Abdominal pain frequency was assessed using the corresponding IBS-SSS domain based on the number of days with abdominal pain during the previous 10 days. The domain score ranges from 0 to 100, with higher scores indicating more frequent abdominal pain. A negative change indicates improvement.
Change From Baseline in Abdominal Bloating Severity at Week 6Baseline and Week 6Abdominal bloating severity, including feelings of distension, fullness, and gas, was assessed using the corresponding IBS-SSS domain, scored from 0 to 100. Higher scores indicate greater symptom severity. A negative change indicates improvement.
Change From Baseline in Dissatisfaction With Bowel Habits at Week 6Baseline and Week 6Dissatisfaction with bowel habits was assessed using the corresponding IBS-SSS domain, scored from 0 to 100. Higher scores indicate greater dissatisfaction with bowel habits. A negative change indicates improvement.
Change From Baseline in Interference of Bowel Symptoms With Daily Life at Week 6Baseline and Week 6The interference of bowel symptoms with daily life was assessed using the corresponding IBS-SSS domain, scored from 0 to 100. Higher scores indicate greater interference with daily life. A negative change indicates improvement.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026